| Evaluated miRNA(s) | Study type | Involved cells/in vivo model/clinical samples | Target(s) | Pathway | Functions | Dysregulation (up/down) | Species | References |
| miR-20b | In vivo | Osteocytes and rat | BMP | BMP | Block the angiogenesis in bone tissues, promoting osteocyte apoptosis | Up | Rat | [26] |
| miR-7 | In vitro | Osteoblasts | EGFR | EGFR/Akt | Promote osteoblast death | Up | Human | [56] |
| miR-217 | In vitro | BMSCs | DKK1 | — | Promote cell proliferation and osteogenic differentiation | Down | Human | [27] |
| miR-27a | In vivo and vitro | Preosteoblasts and rat | TGF-β and Smad7 | TGF-β/Smad7 | Promote osteogenic differentiation and increase proliferation | Down | Human and rat | [28] | In vivo and vitro | mBMSCs and rat | PPARγ and GREM1 | PPARγ | Suppress adipogenesis and enhance osteogenesis | Down | Rat | [21] |
| miR-320 | In vivo and in vitro | Human ONFH tissue and rat | CYP1A2 | — | Inhibit the occurrence and development of ONFH | Down | Human and rat | [29] |
| miR-206 | In vitro | Osteoblasts | PDCD4 | — | Decrease cell viability and proliferation, while apoptosis was induced | Up | Human | [30] | In vivo and in vitro | Osteoblasts and rabbit | Cx43 | Wnt/β-catenin | Inhibit the differentiation of osteoblasts | Up | Rabbit | [31] |
| mir-34a | In vivo and in vitro | mBMSCs, HUVECs, and rat | Runx2 | — | BMSCs: Promote osteogenic differentiation and increase proliferation HUVECs: acute inhibitory effect on angiogenesis in the early stage of steroid-induced ONFH, but it disturbed the normal vascular reparative process in the compensatory phase, which then indirectly aggravates ONFH. | Down in mBMSCs, and up in HUVECs | Human and rat | [32] | In vivo | Rat serum | Tgif2 | OPG/RANK/RANKL | Alleviate ONFH | Down | Rat | [33] | In vitro and in vivo | mBMSCs and mice | CDK4, CDK6, and cyclin D1 | JAG1/Notch | Inhibit BMSCs proliferation and osteoblastic differentiation | Up | Mice | [34] |
| miR-181d | In vitro | hBMSCs | Smad3 | Smad3 | Inhibit osteobalsitc differentiation of BMSCs | Up | Human | [35] |
| miR-200a | In vitro | Osteoblasts | Keap1/Nrf2 | Nrf2 | Protect osteoblasts from dex | Down | Human | [36] |
| miR-146a | In vitro | Murine osteoblasts | Bcl2 | Bcl2 | Inhibits proliferation and induce apoptosis | Up | Murine | [37] | In vivo | Rabbit | Wnt | Wnt/β-catenin | Promote angiogenesis; inhibited the apoptosis of bone cells | Up | Rabbits | [38] |
| miR-145 | In vivo and in vitro | Human THP-1 cells and rat | OPG | OPG/(RANKL)/RANK | Inhibit osteoclast differentiation and prevent excessive bone resorption | Down | Human and rat | [39] |
| miR-25-5p | In vitro | Osteoblasts | PKCζ | AMPK | Protect osteoblasts from steroid | Up | Human | [40] |
| miR-23a-3p | In vivo and in vitro | mBMSCs and rat | LRP5 | — | Inhibit osteogenic differentiation | Up | Rat | [41] |
| miR-708 | In vivo and in vitro | hBMSCs | Smad3 | Smad3 | Inhibit osteogenic differentiation and enhance adipogenesis differentiation | Up | Human | [20] |
| miR-210 | In vivo and invitro | HUVECs and rat | — | — | activate the angiogenesis | Up | Human and rat | [18] |
| miR-135b | In vitro | Osteoblastic | Ppm1e | AMPK | Protects osteoblasts from steroid | Up | Human | [42] |
| mir-199a-5p | In vivo and intro | Osteoblasts and rat | Wnt | FZD4, WNT2 | Inhibit cell proliferation in differentiating osteoblasts | Up | Human and rat | [43] |
| miR-548d-5p | In vitro | hBMSCs | PPARγ | PPARγ | Suppress steroid-induced adipogenic differentiation of and enhance osteogenic potential. | Down | Human | [44] |
| miR-17/20a | In vivo and vitro | Osteoblasts and rat | RANKL | RANKL | Inhibit steroid-induced osteoclast differentiation | Down | Human and rat | [45] |
|
|
Note. miRNAs, microRNAs; ONFH, osteonecrosis of the femoral head; BMSCs, bone marrow mesenchymal stem cells; GREM1, gremlin 1; BMP, bone morphogenesis protein; EGFR, epidermal growth factor receptor; DKK1, dickkopf-related protein 1; TGF-β, transforming growth factor-β; PPARγ, peroxisome proliferator-activated receptor gamma; Runx2, Runt-related transcription factor 2; CYP1A2, cytochrome P450 1A2; PDCD4, programmed cell death protein 4; Cx43, Connexin43; HUVECs, human umbilical vein endothelial cells; Tgif2, transforming growth factor-beta-induced factor homeobox 2; OPG, osteoprotegerin; RANK, Receptor activator of nuclear factor B; RANKL, receptor activator of nuclear factor B ligand; Nrf2, NF-E2-related factor 2; Bcl2, B-cell lymphoma-2; PKCζ, protein kinase C ζ; AMPK, AMP-activated protein kinase; LRP-5, low-density lipoprotein receptor-related protein 5.
|